| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total revenues | 71,638 | 63,742 | ||
| Cost of sales | 17,712 | 16,230 | ||
| Gross profit | 53,926 | 47,512 | ||
| Selling, general and administrative | 35,856 | 33,235 | ||
| Research and development | 3,323 | 2,868 | ||
| Total operating expenses | 39,179 | 36,103 | ||
| Income (loss) from operations | 14,747 | 11,409 | ||
| Interest expense, net | 6,038 | 6,408 | ||
| Loss on extinguishment of debt | -7,750 | - | ||
| Investment loss from eton pharmaceuticals | - | 0 | ||
| Other income, net | 61 | -6 | ||
| Total other expense, net | -13,727 | -6,414 | ||
| Income (loss) before income taxes | 1,020 | 4,995 | ||
| Income tax expense | - | 0 | ||
| Net income (loss) | 1,020 | 4,995 | ||
| Basic net income (loss) per share of common stock | 0.03 | 0.14 | ||
| Diluted net income (loss) per share of common stock | 0.03 | 0.13 | ||
| Weighted average number of shares of common stock outstanding, basic | 37,145,440 | 36,790,306 | ||
| Weighted average number of shares of common stock outstanding, diluted | 38,875,005 | 38,853,855 | ||
HARROW, INC. (HROWL)
HARROW, INC. (HROWL)